Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial

被引：5
|
作者：
Briones, Javier [1 ]
Novelli, Silvana [1 ]
Garcia-Marco, Jose A. [2 ]
Tomas, Jose F. [3 ]
Bernal, Teresa [4 ]
Grande, Carlos [5 ]
Canales, Miguel A. [6 ]
Torres, Antonio [7 ]
Moraleda, Jose M. [8 ]
Panizo, Carlos [9 ]
Jarque, Isidro [10 ]
Palmero, Francisca [11 ]
Hernandez, Miguel [12 ]
Gonzalez-Barca, Eva [13 ]
Lopez, Dulce [1 ]
Caballero, Dolores [14 ]
机构：
[1] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[2] Hosp Univ Puerta de Hierro, Madrid, Spain
[3] MD Anderson Int, Madrid, Spain
[4] Hosp Univ Cent Asturias, Oviedo, Spain
[5] Hosp 12 Octubre, E-28041 Madrid, Spain
[6] Hosp La Paz, Madrid, Spain
[7] Hosp Reina Sofia, Cordoba, Spain
[8] Hosp Virgen Arrixaca, Murcia, Spain
[9] Univ Navarra Clin, Pamplona, Spain
[10] Hosp Univ La Fe, Valencia, Spain
[11] Hosp Univ Alicante, Alicante, Spain
[12] Hosp Univ Canarias, Tenerife, Spain
[13] ICO Duran & Reynals, Barcelona, Spain
[14] Hosp Univ Salamanca, Salamanca, Spain
来源：
HAEMATOLOGICA | 2014年 / 99卷 / 07期
关键词：
diffuse large B-cell lymphoma; ibritumomab tiuxetan; autologous transplantation; relapse;
D O I：
10.3324/haematol.2014.108308
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma
    Kang, Byung Woog
    Kim, Won Seog
    Kim, Chul
    Jang, Geundoo
    Lee, Sung Sook
    Choi, Yoon Hee
    Lee, Dae Ho
    Kim, Sang We
    Kim, Shin
    Ryu, Jin-Sook
    Huh, Jooryung
    Lee, Jung Shin
    Suh, Cheolwon
    INVESTIGATIONAL NEW DRUGS, 2010, 28 (04) : 516 - 522
  • [22] Current status and future perspectives for yttrium-90 (90Y)-ibritumomab tiuxetan in stem cell transplantation for non-Hodgkin's lymphoma
    C Gisselbrecht
    W Bethge
    R F Duarte
    A M Gianni
    B Glass
    C Haioun
    G Martinelli
    A Nagler
    R Pettengell
    A Sureda
    H Tilly
    K Wilson
    Bone Marrow Transplantation, 2007, 40 : 1007 - 1017
  • [23] Radioimmunotherapy with Yttrium-90 Ibritumomab tiuxetan for patients with relapsed cd20+ B-Cell non-Hodgkin’s Lymphoma
    Alcindor T.
    Witzig T.E.
    Current Treatment Options in Oncology, 2002, 3 (4) : 275 - 282
  • [24] Assessment of Metabolic Response to Radioimmunotherapy (RIT) with Yttrium-90 (Y-90) Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma
    Storto, G.
    Nardelli, A.
    Pellegrino, T.
    Perna, F.
    De Falco, T.
    Erra, P.
    Ortosecco, G.
    Castaldi, E.
    Speranza, A.
    Klain, M.
    De Renzo, A.
    di Nuzzo, C.
    Pace, L.
    Rotoli, B.
    Salvatore, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S148 - S148
  • [25] Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
    Wiseman, Gregory A.
    Conti, Peter S.
    Vo, Katie
    Schilder, Russell J.
    Gordon, Leo I.
    Emmanouilides, Christos
    Silverman, Dan H.
    Witzig, Thomas E.
    Darif, Mohamed
    Molina, Arturo
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (08): : 514 - 517
  • [26] INTERIM ANALYSIS OF POST MARKETING SURVEILLANCE OF YTTRIUM-90 IBRITUMOMAB TIUXETAN IN JAPANESE PATIENTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA OR MANTLE CELL LYMPHOMA
    Hatake, K.
    Kanzaki, R.
    Yabuuchi, Y.
    Kataoka, O.
    Nagai, S.
    Asaeda, Y.
    HAEMATOLOGICA, 2016, 101 : 273 - 273
  • [27] Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma
    Krishnan, Amrita
    Nademanee, Auayporn
    Fung, Henry C.
    Raubitschek, Andrew A.
    Molina, Arturo
    Yamauchi, Dave
    Rodriguez, Roberto
    Spielberger, Ricardo T.
    Falk, Peter
    Palmer, Joycelynne M.
    Forman, Stephen J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (01) : 90 - 95
  • [28] 90Y-Ibritumomab Tiuxetan as Consolidation Therapy After Autologous Stem Cell Transplantation in Aggressive Non-Hodgkin Lymphoma
    Ria, Roberto
    Musto, Pellegrino
    Reale, Antonia
    Guariglia, Roberto
    Iodice, Giuseppe
    Dammacco, Franco
    Vacca, Angelo
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (06) : 891 - 895
  • [29] Experience with yttrium 90 ibritumomab tiuxetan after autologous stem cell transplant (ASCT) in patients with non-Hodgkin's lymphoma (NHL).
    Joyce, J
    Schuster, MW
    McCook, B
    Torok, F
    Avril, N
    Vidnovic, N
    Jacobs, SA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 602S - 602S
  • [30] The use of Yttrium-90 Ibritumomab Tiuxetan (Y-90-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transplantation
    Jurczak, Wojciech
    Kisiel, Elzbieta
    Sawczuk-Chabin, Joanna
    Centkowski, Piotr
    Knopinska-Posluszny, Wanda
    Khan, Omeir
    WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2015, 19 (01): : 43 - 47
12345